Vanda Pharmaceuticals Inc.

Form 4/A

December 18, 2015

OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... 0.5 Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading

3. Date of Earliest Transaction

Vanda Pharmaceuticals Inc. [VNDA]

Symbol

5. Relationship of Reporting Person(s) to

(Check all applicable)

Issuer

(Print or Type Responses)

1. Name and Address of Reporting Person *

(First)

(Middle)

See Instruction

1(b).

Flynn James E

(Last)

780 THIRD AVENUE, 37TH FLOOR,			/Day/Year) /2015)			DirectorX 10% Owner Officer (give titleX Other (specify below) Possible Member of 10% Group			
Filed			mendment, Ionth/Day/Y	Date Origina ear)	1		6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person			
NEW YORK, NY 10017							_X_ Form filed by More than One Reporting Person			
(City)	(State)	(Zip) Ta	ble I - Non	-Derivative	Secur	ities Acqu	iired, Disposed of	f, or Benefici	ally Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securitie onor Disposed (Instr. 3, 4	d of (I	O)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	12/10/2015		P	32,211 (<u>5)</u>	A	\$ 8.5902 (1)	2,048,598 (5)	I	Through Deerfield Partners, L.P. (3) (4)	
Common Stock	12/10/2015		P	40,997 (5)	A	\$ 8.5902 (1)	2,607,307 (5)	I	Through Deerfield International Master Fund, L.P. (3) (4)	
Common Stock	12/10/2015		P	29,902	A	\$ 8.5902 (1)	1,006,744	I	Through Deerfield Special	

								Situations Fund, L.P. (3) (4)
Common Stock	12/11/2015	P	100,864	A	\$ 8.6089 (2)	2,149,462 (5)	I	Through Deerfield Partners, L.P. (3) (4)
Common Stock	12/11/2015	P	128,374	A	\$ 8.6089	2,735,681 (5)	I	Through Deerfield International Master Fund, L.P. (3) (4)
Common Stock	12/11/2015	P	93,634	A	\$ 8.6089 (2)	1,100,378	I	Through Deerfield Special Situations Fund, L.P. (3) (4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

 $\label{thm:convergence} \begin{tabular}{ll} Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned \\ (e.g., puts, calls, warrants, options, convertible securities) \end{tabular}$

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transact Code (Instr. 8)	5. SorNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	5	ate	Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address Relationships

Reporting Owners 2

Director 10% Owner Officer Other

Flynn James E 780 THIRD AVENUE, 37TH FLOOR NEW YORK, NY 10017	X	Possible Member of 10% Group
Deerfield Mgmt L.P. 780 THIRD AVENUE, 37TH FLOOR NEW YORK, NY 10017	X	Possible Member of 10% Group
DEERFIELD MANAGEMENT CO 780 THIRD AVENUE, 37TH FLOOR NEW YORK, NY 10017	X	Possible Member of 10% Group
Deerfield International Master Fund, L.P. 780 3RD AVENUE 37TH FLOOR NEW YORK, NY 10017	X	Possible Member of 10% Group
DEERFIELD PARTNERS, LP 780 THIRD AVENUE, 37TH FLOOR NEW YORK, NY 10017	X	Possible Member of 10% Group
Deerfield Special Situations Fund, L.P. 780 3RD AVENUE 37TH FLOOR NEW YORK, NY 10017	X	Possible Member of 10% Group

Signatures

/s/ Jonathan Isler 12/18/2015

**Signature of Date
Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from \$8.50 to \$8.65, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) of this Form 4.
- (2) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from \$8.50 to \$8.655, inclusive.
 - This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt, L.P. is the general partner of Deerfield Special Situations Fund, L.P.
- (3) ("DSS"), Deerfield Partners, L.P. ("DP") and Deerfield International Master Fund, L.P. ("DFIM," and together with DSS and DP, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P. and Deerfield Management Company, L.P.
- In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
 - This Amendment to the Form 4 filed with the Commission on December 11, 2015 (the "Original Filing") is being filed to correct an error, whereby (i) 40,997 shares of common stock purchased by DFIM were inadvertently reported as being purchased by DP, (ii)
- (5) 32,211 shares of common stock purchased by DP were inadvertently reported as being purchased by DFIM. This amendment also corrects resulting errors in the number of shares of common stock beneficially owned by DP and DFIM following such transactions. The aggregate number of shares acquired by the Funds, as reflected in the Original Filing, remains unchanged.

Signatures 3

Edgar Filing: Vanda Pharmaceuticals Inc. - Form 4/A

Remarks:

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.